Immunohistochemical Expression of Platelet-Derived Growth Factor Receptors in Ovarian Cancer Patients with Long-Term Follow-Up
Figure 1
Examination of antibody specifities. Original magnification 100. (a) Immunostaining with the primary antibody for PDGFR-α (SC-338) (b) Addition of blocking peptides for PDGFR-α (SC-338P) to the primary antibody for PDGFR-α, resulting in a significantly reduced staining reaction. (c) Addition of blocking peptide for PDGFR-β (SC-339P) to primary antibody for PDGFR-α, with no visible reduction in the staining intensity. (d) Immunostaining with the primary antibody for PDGFR-β (SC-339) (e) Addition of blocking peptides for PDGFR-β (SC-339P) to primary antibody for PDGFR-β, resulting in a significantly reduced staining reaction. (f) Addition of blocking peptide for PDGFR-α to antibody for PDGFR-β, with no visible reduction in the staining intensity.